
    
      The study included:

        -  A screening visit of up to 21 days prior to randomization

        -  Randomization at baseline (Treatment was initiated with 3 days of randomization)

        -  A treatment period with 3-week treatment cycles until the participant met the following
           discontinuation criteria: had progressive disease, had unacceptable toxicity, or refused
           further study treatment

        -  A post study treatment follow-up period (a visit was scheduled every 8 weeks until death
           or end of study)
    
  